These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 24183296)

  • 41. Fatal interstitial lung disease associated with high erlotinib and metabolite levels. A case report and a review of the literature.
    ter Heine R; van den Bosch RT; Schaefer-Prokop CM; Lankheet NA; Beijnen JH; Staaks GH; van der Westerlaken MM; Malingré MM; van den Brand JJ
    Lung Cancer; 2012 Mar; 75(3):391-7. PubMed ID: 22101147
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Significant drug interaction: phenytoin toxicity due to erlotinib.
    Grenader T; Gipps M; Shavit L; Gabizon A
    Lung Cancer; 2007 Sep; 57(3):404-6. PubMed ID: 17383767
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fatal interstitial lung disease after erlotinib administration in a patient with radiation fibrosis.
    Um SJ; Lee SK; Yang DK; Son C; Roh MS; Kim KN; Lee KN; Choi PJ
    Clin Respir J; 2009 Jul; 3(3):181-4. PubMed ID: 20298401
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer.
    Kiyohara Y; Yamazaki N; Kishi A
    J Am Acad Dermatol; 2013 Sep; 69(3):463-72. PubMed ID: 23602600
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Erlotinib in the treatment of non-small cell lung cancer: current status and future developments.
    Gridelli C; Maione P; Bareschino MA; Schettino C; Sacco PC; Ambrosio R; Barbato V; Falanga M; Rossi A
    Anticancer Res; 2010 Apr; 30(4):1301-10. PubMed ID: 20530444
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy vs. effectiveness: erlotinib in previously treated non-small-cell lung cancer.
    Sheikh N; Chambers CR
    J Oncol Pharm Pract; 2013 Sep; 19(3):228-36. PubMed ID: 23175450
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of adverse events of erlotinib with those of gefitinib in patients with non-small cell lung cancer: a case-control study in a Japanese population.
    Suzumura T; Kimura T; Kudoh S; Umekawa K; Nagata M; Tanaka H; Mitsuoka S; Yoshimura N; Kira Y; Hirata K
    Osaka City Med J; 2012 Jun; 58(1):25-34. PubMed ID: 23094511
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.
    Wheatley-Price P; Ding K; Seymour L; Clark GM; Shepherd FA
    J Clin Oncol; 2008 May; 26(14):2350-7. PubMed ID: 18467727
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Efficacy and toxicity of erlotinib in non-small cell lung cancer treatment].
    Romero-Ventosa EY; Mucientes-Molina A; Pedrido-Reino E; Lago-Rivero N; Constenla-Caramés L; Arias-Santos I
    Farm Hosp; 2012; 36(2):68-76. PubMed ID: 21798783
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer.
    Pérez-Soler R; Chachoua A; Hammond LA; Rowinsky EK; Huberman M; Karp D; Rigas J; Clark GM; Santabárbara P; Bonomi P
    J Clin Oncol; 2004 Aug; 22(16):3238-47. PubMed ID: 15310767
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pulmonary toxicity associated with erlotinib.
    Liu V; White DA; Zakowski MF; Travis W; Kris MG; Ginsberg MS; Miller VA; Azzoli CG
    Chest; 2007 Sep; 132(3):1042-4. PubMed ID: 17873198
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An inflammatory response with worsening of pleural effusion on treatment with erlotinib in non-small cell lung cancer.
    Toh CK; Lee P; Chowbay B; Goh JW; Mancer K; Tan PH
    Acta Oncol; 2007; 46(2):256-8. PubMed ID: 17453379
    [No Abstract]   [Full Text] [Related]  

  • 53. Erlotinib-induced rash spares previously irradiated skin.
    Lips IM; Koster ME; Houwing RH; Vonk EJ
    Strahlenther Onkol; 2011 Aug; 187(8):499-501. PubMed ID: 21789741
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Erlotinib induced target-like purpura.
    Rungtrakulchai R; Rerknimitr P
    Dermatol Online J; 2014 Feb; 20(2):. PubMed ID: 24612572
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hand-foot syndrome induced by erlotinib (Tarceva(Ⓡ) ).
    Cho YS; Park J; Kim JI; Nam KH; Yun SK; Kim HU
    Int J Dermatol; 2014 Mar; 53(3):e190-2. PubMed ID: 23675736
    [No Abstract]   [Full Text] [Related]  

  • 56. Atypical response to erlotinib in a patient with metastatic lung adenocarcinoma: a case report.
    Sakhri L; Meynet E; Ferrer L; Pirvu A; Ferretti G; Moro-Sibilot D
    J Med Case Rep; 2014 Oct; 8():335. PubMed ID: 25301323
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Subacute transient encephalopathy induced by erlotinib.
    Okyuama T; Akazawa Y; Uchida J; Nishino K; Kumagai T; Imamura F
    Oncol Res; 2011; 19(8-9):399-402. PubMed ID: 22329199
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Erlotinib-associated acute pneumonitis: report of two cases.
    Vahid B; Esmaili A
    Can Respir J; 2007 Apr; 14(3):167-70. PubMed ID: 17464382
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A case of radiation recall pneumonitis induced by erlotinib, which can be related to high plasma concentration.
    Togashi Y; Masago K; Mishima M; Fukudo M; Inui K
    J Thorac Oncol; 2010 Jun; 5(6):924-5. PubMed ID: 20502274
    [No Abstract]   [Full Text] [Related]  

  • 60. Ocular side effects and trichomegaly of eyelashes induced by erlotinib: a case report and review of the literature.
    Celik T; Kosker M
    Cont Lens Anterior Eye; 2015 Feb; 38(1):59-60. PubMed ID: 25249292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.